While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...

DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2, subcutaneous semaglutide reduced the ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...